Structured Development of Value-Added Specialty Medicines
Arenyx Pharma is a specialty pharmaceutical company developing value-added and complex medicines using a proprietary, data-driven candidate selection platform.
About ARENYXPHARMA
Transforming pharmaceutical development through structured multi-factor evaluation model
Mission
To industrialize the selection of high-value pharmaceutical development pathways, eliminating guesswork and accelerating the delivery of critical medicines to patients.
Vision
A future where every drug development decision is data-driven, risk-optimized, and capital-efficient—powered by proprietary selection framework that removes the intuition gap.
Approach
We combine regulatory science, real-world evidence, and structured multi-factor evaluation model to identify 505(b)(2) and Hybrid pathways with the highest probability of approval and commercial success.
Leadership
Founded by executives with 20+ years of experience in generics, 505(b)(2), global licensing, and portfolio strategy.
Platform
A structured internal framework guiding candidate selection and portfolio construction
The framework integrates regulatory precedent, historical approval patterns, and commercial analog benchmarking into a unified scoring model.
Platform is currently in development (pre-seed stage)
Data Aggregation
Comprehensive collection of regulatory, clinical, and market data from FDA databases, clinical trial registries, and real-world evidence sources.
Pathway Analysis
Structured evaluation of 505(b)(2) and Hybrid regulatory pathways, identifying approvability gaps and clinical development requirements.
Risk Scoring
Quantitative assessment of technical, regulatory, and commercial risks using data-driven pathway assessment and historical precedent analysis.
Value Optimization
ROI modeling and portfolio optimization to maximize capital efficiency and strategic value across the development pipeline.
Development Pipeline
High-probability 505(b)(2) and Hybrid programs
ARX01
Once Daily XR Formulation
Indication
Neuropathic pain / depression
Rationale
Smoother PK profile vs. IR
Differentiation
✓ Formulation IP
Regulatory Path
US 505(b)(2) / EU Hybrid
ARX02
Solid Oral Conversion
Concept
Bioequivalent oral solid conversion
Rationale
Accelerates patient discharge
Differentiation
✓ Use Setting + Form
Regulatory Path
PK Bridge Strategy
ARX03
Site-Specific Delivery
Concept
Systemic to localized reformulation
Rationale
Avoid systemic adverse events
Differentiation
✓ Formulation Barrier
Regulatory Path
Local PK / BE
EU Strategy Execution
Bridging the gap between global assets and European market realization
ARENYX PHARMA BV - EU Value Creation Partner for Specialty Pharmaceuticals
The European market offers immense potential for specialty pharmaceuticals. We provide specialized execution capabilities to unlock value in the complex European landscape.
EU Market Access
Navigate complex European regulatory pathways (EMA Hybrid/Informed Consent) and national market requirements
Strategic Partnerships
Establish European commercial partnerships and licensing agreements for specialty pharmaceutical assets
Operational Excellence
20+ years of EU pharmaceutical experience in commercialization, supply chain, and market execution
Market Opportunity
Strong global pipelines often face critical bottlenecks entering the complex European landscape
Opportunity lies in execution, not discovery
EU Collaboration Models
Flexible partnership structures tailored to asset stage and partner objectives
License-In for EU
Full EU commercialization rights for approved or late-stage assets
- Arenyx assumes EU regulatory filings and market authorization
- Partner retains ROW rights and receives milestone + royalty payments
- Ideal for global innovators seeking EU-focused partner
Co-Development Partnership
Shared development and commercialization for EU market
- Joint investment in EU clinical trials and regulatory strategy
- Shared economics based on contribution split
- Arenyx leads EU-specific execution (regulatory, commercial)
Strategic Services Agreement
EU market access and partnership facilitation services
- Regulatory strategy consulting for EMA pathways
- Partner identification and deal facilitation
- Market access and reimbursement strategy
Our Value Delivery Framework
Regulatory Expertise
EMA Hybrid, Informed Consent, national pathways
Network Access
Established relationships with EU commercial partners
Commercial Execution
20+ years EU pharma commercialization experience
Market Intelligence
Deep understanding of European reimbursement landscape
Investor Value Proposition
De-risked pharmaceutical development with superior capital efficiency
Reduced Development Risk
Leveraging established safety data and regulatory precedent to minimize clinical trial uncertainty and accelerate approval timelines.
Capital Efficiency
Structured pathway selection prioritizes programs where regulatory precedent enables reduced clinical scope and capital intensity versus full NDA development.
Accelerated Timelines
Deterministic pathway selection and streamlined clinical development compress time-to-market by 3-5 years versus traditional approaches.
Strategic Optionality
Portfolio approach with multiple high-probability assets creates diversified value and attractive exit opportunities at multiple inflection points.
Get In Touch
Connect with our team to learn more about our technology and pipeline